What is Aushon BioSystems?
Aushon BioSystems operates at the intersection of biotechnology and precision instrumentation. The company specializes in the development of advanced microarray technologies, providing researchers with the tools necessary for complex DNA, RNA, and protein analysis. By offering both hardware solutions—such as high-precision arrayers—and comprehensive printing and processing services on diverse substrates like microtiter plates and silicon-based formats, Aushon enables critical breakthroughs in molecular diagnostics and disease research.
Its market position is defined by its versatility, supporting the entire spectrum of the drug development pipeline. From early-stage discovery to clinical diagnostic test development, Aushon provides the infrastructure required to translate biological data into actionable insights, maintaining a competitive edge through its specialized technical expertise and broad service portfolio.
How much funding has Aushon BioSystems raised?
Aushon BioSystems has raised a total of $22.3M across 4 funding rounds:
Unspecified
$2M
Unspecified
$5.5M
Private Equity
$8M
Private Equity
$6.7M
Unspecified (2011): $2M, investors not publicly disclosed
Unspecified (2012): $5.5M, investors not publicly disclosed
Private Equity (2014): $8M supported by North Bridge Venture Partners
Private Equity (2016): $6.7M, investors not publicly disclosed
Key Investors in Aushon BioSystems
North Bridge Venture Partners
North Bridge Venture Partners is a venture capital firm that provides seed-to-growth financing to innovative startups with the potential to disrupt established industries. They focus on transforming early-stage ventures into market leaders through strategic support and capital investment.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Aushon BioSystems?
With the recent injection of capital, Aushon BioSystems is well-positioned to expand its footprint in the global diagnostics market. The strategic focus will likely shift toward enhancing the throughput and sensitivity of its microarray platforms, ensuring they remain at the forefront of the rapidly evolving life-sciences landscape. As the company transitions into this next phase of enterprise-level growth, it is expected to leverage its existing partnerships to deepen its penetration into pharmaceutical and biotech research sectors.
The firm's ability to maintain consistent growth through successive funding rounds suggests a robust long-term strategy centered on innovation and operational excellence. Future initiatives will likely prioritize the integration of new substrate technologies and the scaling of its diagnostic service offerings to meet the increasing demand for high-fidelity molecular analysis in clinical settings.
